Key facts on HIV
Treatment
eMTCT
n/a
HIV Testing Coverage
Data not available
Zero Discrimination
Law and policies that enable independent consent for young people to access HIV testing and related services
Stigma Index
Data not available
Intimate Partner Violence
Data not available
* n/a = Data not available
Community-led Monitoring in Country Proposals for the Global Fund 2023–2025 Funding Cycle (NFM4)
- Released in
This information brief is intended for key population networks and other community-led and community-based organizations to help them better understand how to request funding support for community-led monitoring (CLM) in 2023-2025 applications to the Global Fund. The brief has been jointly developed by TREAT Asia/amfAR and the International Treatment Preparedness Coalition (ITPC).
Global Tuberculosis Report 2022
- Released in
The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data.
Pediatric Dolutegravir: Securing Access to Dispersible Tablets for Children in the Asia-Pacific
- Released in
Facilitating access to formulations of the HIV medicine dolutegravir (DTG) that can be used by infants and children living with HIV in the Asia-Pacific is an urgent concern.
In light of recent U.S. and European regulatory approvals of a dispersible version of pediatric DTG, amfAR’s TREAT Asia program recommends steps that national HIV programs and advocacy groups can take in order to secure access to this medicine as quickly as possible.
Pandemic triad: HIV, COVID-19 and debt in developing countries
- Released in
This report analyses the intersection of HIV, COVID-19 and public debt in developing countries. The collision between COVID-19 and a crippling debt crisis have reversed decades of progress - putting present and future investments in health and HIV at risk. Pragmatic options to address the pandemic triad are proposed.
Integrated HIV Bio-behavioral surveillance survey (IBBS) among female entertainment workers in Cambodia, 2022
- Released in
The main goal of the study was to estimate the prevalence of HIV, syphilis, Chlamydia and Gonorrhoea among female entertainment workers in Cambodia.
Putting Young Key Populations First — HIV and Young People from Key Populations in the Asia and Pacific Region 2022
- Released in
This report describes the HIV epidemic among young people from key populations in the region, takes stock of HIV programmes for such people, and pinpoints the priority actions that will speed up progress towards ending the AIDS epidemic as a public health threat in the region.
IN DANGER: UNAIDS Global AIDS Update 2022
- Released in
Progress in prevention and treatment is faltering around the world, putting millions of people in grave danger. Eastern Europe and central Asia, Latin America, and the Middle East and North Africa have all seen increases in annual HIV infections over several years. In Asia and the Pacific, UNAIDS data now show new HIV infections are rising where they had been falling. Action to tackle the inequalities driving AIDS is urgently required to prevent millions of new HIV infections this decade and to end the AIDS pandemic.
Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact
- Released in
These guidelines focus on the collection and use of person-centred data across the HIV cascade – from prevention, testing and treatment to longer-term health care – building upon 2017 and 2020 strategic information guidelines. The updated guidelines present a standard minimum dataset, priority indicators and recommendations to strengthen data use across HIV prevention, testing and treatment, and linkages to services for sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer.